TyG emerged as a new force, which was shown to be superior to homeostasis model assessment-insulin resistance (HOMA-IR) in evaluating IR, especially for diabetes individuals receiving insulin therapy or without functioning beta cells [35, 36]. This evidence concerns the gene INS and diabetes mellitus.